Monte Rosa posts Q4 net loss $46.1M; cash runway into 2029; positive Phase 1 data for NEK7 degrader MRT-8102

Monte Rosa Therapeutics, Inc.

Q4 net loss $46.1M vs $13.4M in Q4 2024; full-year net loss decreased to $38.6M from $72.7M.
Cash, equivalents, securities $382.1M at Dec 31, 2025; $345M Jan 2026 offering extends runway into 2029.
Interim Phase 1 data for NEK7 degrader MRT-8102: 85% CRP reduction in elevated CVD-risk subjects; unblinded safety shows no SAEs.
Plans to initiate multiple Phase 2 studies of MRT-8102 in H2 2026 (ASCVD, gout, hidradenitis suppurativa).
MRT-2359 in mCRPC with AR mutations: 100% PSA response rate; Phase 2 with apalutamide planned Q3 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.